Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434200 | 0.88 | OPRM1 (0.48) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3389827 | 0.88 | OPRM1 (0.39) | HRH3OPRM1OPRD1OPRK1EGLN1 | |
| SCHEMBL3384977 | 0.88 | OPRM1 (0.47) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3386217 | 0.87 | HRH3 (0.41) | HRH3EGLN1KCNH2 | |
| SCHEMBL3385401 | 0.87 | HRH3 (0.41) | HRH3EGLN1KCNH2 | |
| SCHEMBL3385475 | 0.83 | DRD2 (0.47) | HRH3HTR1ADRD2HTR2A | |
| SCHEMBL3385417 | 0.82 | HTR1A (0.43) | HTR1ADRD2HTR2AFFAR1KCNH2 | |
| SCHEMBL3386233 | 0.81 | DRD2 (0.43) | HRH3HTR1ADRD2HTR2A | |
| SCHEMBL3389254 | 0.81 | TMEM97 (0.43) | HRH3HTR1ADRD2HTR2AKCNH2 | |
| SCHEMBL13652075 | 0.80 | HRH3 (0.39) | HRH3DRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | claimed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | claimed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | claimed |
| EP-1756104-B1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | PFIZER LTD (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | LUNN GRAHAM | 2009-10-15 | — | — | US | disclosed |
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | disclosed |
| EP-1595881-A1 | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands | Pfizer Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | HRH3 2/4885OPRM1 244/4885OPRD1 134/4885 |
| US-20090258861-A1 | Tetrahydronaphthyridine Derivatives | HRH4, HRH3, HRH1 | HRH3 2/4885OPRM1 244/4885OPRD1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.